Enhanced expression of CDC20 is more often found in various tumor types (including lung adenocarcinoma, breast cancer, bladder cancer and prostate cancer) and might serve as a novel cluster of prognostic biomarkers28–31. This evidence concerns the gene CDC20 and prostate cancer.